Home > Boards > US Listed > Medical - Healthcare > Iovance BiotherapeutIcs (IOVA)

TIL in HPV associated cancer. The ORR was

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 14
Posts 846
Boards Moderated 2
Alias Born 10/24/15
160x600 placeholder
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire Inc. - 9/27/2019 4:30:00 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/25/2019 6:00:54 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/17/2019 4:12:47 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/30/2019 5:03:11 PM
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire Inc. - 8/26/2019 4:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 5:03:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:07:54 PM
Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/1/2019 4:01:00 PM
Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019... GlobeNewswire Inc. - 7/26/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/19/2019 5:17:30 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/19/2019 5:15:59 PM
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer GlobeNewswire Inc. - 7/18/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 8:01:29 AM
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Adm... GlobeNewswire Inc. - 7/2/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 4:46:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/11/2019 5:17:06 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/11/2019 5:16:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 8:00:58 AM
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors GlobeNewswire Inc. - 6/11/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 4:33:06 PM
jondoeuk   Thursday, 12/13/18 03:41:48 PM
Re: None
Post # of 43 
TIL in HPV associated cancer. The ORR was 28% in cervical and 18% in other types https://pbs.twimg.com/media/DtsqGIGVsAAqe9Y.jpg There were two long term responders.

From the paper the authors state: ''In addition, the treatment requires surgery for procurement of a tumor from which to generate TILs, and the generation of high numbers of TILs takes approximately four to six weeks. In the present trial, patients underwent surgery and 29 patients received treatment (Appendix Fig A1, online only).

Another limitation is the patient-to-patient variability in the HPV reactivity of TILs and the infused cell product. Consistent with reports by others, we that TILs from a number of patients possessed no HPV reactivity or low HPV reactivity (Fig 2A and 2B, Appendix Fig A1, online only). In the administered T cells, the frequency of HPV reactivity ranged from ≤0.1 to 31%, median 5% (Fig 2A) and the magnitude of IFNg release ranged from ≤0.1 to 5.6 ng/ml, median 0.2 ng/ml (Fig 2B).

One strategy to circumvent surgery and generate a more consistent HPV oncoprotein-targeted cell product may be to administer HPV-specific T cells that are propagated and enriched ex vivo from peripheral blood. Another strategy may be to administer peripheral blood T cells that are genetically engineered ex vivo to target an HPV oncoprotein with a T cell receptor. We are presently testing this strategy in an active clinical trial with gene engineered T cells that target HPV16 E7 (NCT02858310)''

http://clincancerres.aacrjournals.org/content/early/2018/12/05/1078-0432.CCR-18-2722

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist